Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Picks Teva’s Gerard Greco as Global Quality Officer
September 17, 2014
- Sanofi Taps Call Center to Prevent Patient Dropouts from Insulin Therapy
September 16, 2014
- Pharmacy Chains Hurrying to Reach Price Settlements with Wholesalers ahead of Sept.-End Deadline
September 16, 2014
- Novartis Pharma Paid 22.9 Billion Yen to Healthcare Professionals in 2013
September 16, 2014
- AstraZeneca’s 2013 Payments to Healthcare Professionals Reach 7.5 Billion Yen
September 16, 2014
- JB, MTPC to Cease Sales Collaboration for Plasma Products in March 2015
September 16, 2014
- Takara Bio Pushes for Melanoma Drug Development with Eye on Fast Approval
September 12, 2014
- Shionogi Paid 15.2 Billion Yen to Medical Institutions in FY2013
September 12, 2014
- LEO Pharma Launches Its 1st Product in Japan, with Kyowa Kirin as Distributor
September 12, 2014
- Nobelpharma Collaborates with US Research Institute for Development of Endometriosis Treatment
September 12, 2014
- US FDA Approves Xtandi for Chemotherapy-Naïve Patients with Metastatic CRPC: Astellas
September 12, 2014
- Sawai to Comarket Sandoz’s Filgrastim Biosimilar
September 11, 2014
- Eisai Partners with Kyorin for Utilization of Eisai's Compound Library in Antibacterial Field
September 11, 2014
- Eli Lilly Japan, Hitachi Ink Sales Deal for Radiopharmaceutical Synthesizer for AD-Related Protein Imaging in Japan
September 10, 2014
- Shionogi to Realign Japan Sales Teams, Heed Regional Demands
September 10, 2014
- Zeria’s PMS Treatment Prefemin Now on Sale as “Drug Requiring Guidance”
September 10, 2014
- Janssen Discloses 2013 Payments of 8.3 Billion Yen to Healthcare Professionals
September 10, 2014
- Otsuka to Launch Deltyba on September 26; Launch Delayed in Anticipation of Revised TB Treatment Guidelines
September 10, 2014
- Medical & Biological Lab Seeking Partner for Dengue Fever Drug Development
September 9, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
September 9, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…